Why Certification of Packaging Materials is Critical

Packaging materials are in direct contact with the drug product throughout its shelf life. They can influence the product’s quality, safety, and efficacy. Regulatory agencies require manufacturers to demonstrate that these materials are suitable for use, have been properly tested, and are sourced from approved suppliers. Certification ensures that the packaging components:

• ✓ Meet predefined specifications and pharmacopeial standards (USP, Ph.Eur, JP)
• ✓ Are free from extractables, leachables, or other harmful contaminants
• ✓ Have consistent physical and chemical performance
• ✓ Are backed by complete documentation and change control records

Essential Certificates and Regulatory Documentation

The following documents must be obtained and maintained for each packaging component used in stability studies:

• Certificate of Analysis (CoA): Supplier-issued report confirming batch-wise testing results
• Certificate of Compliance (CoC): Declaration that the product complies with GMP, pharmacopeia, and regulatory expectations
• USP , , , Reports: Documentation of extractables, leachables, and physical properties
• DMF References: Drug Master File references (Type III) for container closure systems filed with the FDA
• Change Notification Policy: Supplier’s commitment to inform about composition or process changes

Key Regulatory Guidelines and Standards

When selecting and certifying packaging materials, manufacturers must refer to key global guidelines, including:

• ICH Q1A(R2): Stability Testing of New Drug Substances and Products
• ICH Q3C/Q3D: Impurities including residual solvents and elemental impurities
• 21 CFR Part 211 and 820: US GMP requirements for packaging
• EU GMP Annex 9: Use of primary and printed packaging materials
• WHO TRS Annexes on Stability and Packaging

Packaging Certification in Regulatory Dossiers

Packaging material certification data must be included in:

• CTD Module 3.2.P.7: Container closure system information
• Module 3.2.R: Regional-specific certifications and GMP declarations
• Risk Assessments: Related to packaging interactions and stability

Failure to provide complete documentation may result in deficiency letters, delayed approvals, or even rejections.

Case Example: EMA Query on Container Closure Declaration

During centralized review, the EMA requested additional data for a parenteral product. The sponsor had failed to submit extractables and leachables data for the rubber stopper. Despite having stability data, approval was delayed by 4 months until appropriate EMA expectations were met with certified reports and supporting risk assessments.

Supplier Qualification and Audit Expectations

Packaging suppliers play a pivotal role in ensuring regulatory compliance. Pharmaceutical companies must:

• ✔ Qualify suppliers through GMP audits and quality questionnaires
• ✔ Obtain CoA and CoC for each shipment or batch used
• ✔ Implement Quality Agreements covering responsibilities and notification clauses
• ✔ Periodically re-evaluate suppliers based on risk and performance

Auditors from regulatory agencies routinely inspect documentation related to supplier qualification, material traceability, and change management.

Testing and Verification of Certified Packaging Materials

Even when a CoA is provided, pharma companies must conduct their own verification testing to confirm compliance:

• Identification by FTIR or other spectroscopic techniques
• Physical inspection (dimensions, weight, torque, clarity)
• Extractables testing if new supplier or change in formulation
• Label and ink testing for migration or solvent compatibility
• Documentation of test results, review by QA

Checklist for Packaging Certification Compliance

• ☑ Have all packaging components undergone extractables and leachables testing?
• ☑ Is the packaging material certified for intended use (e.g., oral, parenteral)?
• ☑ Are all CoA and CoC records traceable and reviewed by QA?
• ☑ Has the supplier been GMP audited within the last 3 years?
• ☑ Are packaging specifications and certificates filed in the product dossier?

Cross-Linking Packaging and Stability Programs

Certifications must directly align with the packaging used in actual stability testing. Using non-certified or alternate packaging will compromise data integrity. As a best practice:

• Link packaging certificate ID with each stability batch record
• Include certificates in stability reports
• Flag packaging-related OOS or trends during stability trending reviews

More on packaging SOPs and documentation can be found at pharma SOPs.

Conclusion

Certifying packaging materials used in stability studies is a critical component of regulatory compliance. Through thorough supplier qualification, verification testing, documentation control, and inclusion in regulatory submissions, pharma manufacturers can safeguard product quality, avoid regulatory delays, and meet global standards. Certification isn’t just paperwork—it’s an assurance of integrity, consistency, and patient safety.

References:

• ICH Q1A(R2), Q3C, Q3D Guidelines
• USP Chapters <661.1>, <661.2>, <671>, <381>
• USFDA Guidance on Container Closure Systems
• EU GMP Annex 9: Packaging Materials
• WHO TRS 1010 Annex 10 – Stability Guidelines

1. Using a Different Container During Stability Studies Than in Marketed Product

This is one of the most cited issues in FDA and EMA reviews. Stability studies must be performed in the final market-intended packaging configuration. Using interim containers during development without bridging studies can result in invalidated data.

• Incorrect: Conducting stability in Type II glass, while commercial pack is HDPE
• Correct: Conducting stability in the same container type, even during early development

If a change is unavoidable, comparative stability and extractables/leachables (E&L) studies must justify equivalence.

2. Missing or Incomplete Container Closure Integrity (CCI) Data

According to USP , CCI testing is mandatory for sterile products. Many submissions fail to provide this data or rely solely on visual inspection.

• Always perform quantitative CCI testing such as vacuum decay, helium leak, or microbial ingress.
• Include results before and after accelerated stability and shipping simulation.
• Document the methods, acceptance criteria, and validation status.

3. Inadequate Extractables and Leachables (E&L) Justification

Missing or generic E&L data is a top reason for regulatory queries. Each container component—vial, stopper, cap—must be evaluated for extractable and leachable substances using validated analytical methods (e.g., LC-MS, GC-MS, ICP-MS).

• Test materials at storage-representative conditions (e.g., 40°C/75% RH)
• Match migration levels with permitted daily exposure (PDE)
• Include worst-case scenarios (e.g., high surface contact, low fill volumes)

4. Lack of Closure System Documentation in CTD

CTD Module 3.2.P.7 requires detailed packaging information. Many dossiers either lack full closure specs or reference outdated vendor files.

Include the following:

• Part numbers, drawings, and material details for each closure
• Validation reports for sealing process and integrity
• Photostability and stress test outcomes
• Change control history and requalification records

Refer to regulatory compliance portals for submission guidance.

5. Choosing Containers Based on Cost or Convenience

Selecting a container based on availability or pricing, rather than compatibility, often leads to compliance issues. Regulators expect evidence that the container does not adversely affect the drug’s quality.

Always conduct compatibility studies covering:

• Assay and impurity profile changes
• pH, color, or odor shifts
• Adsorption of API on the container walls

Document findings in both development reports and regulatory files.

6. Ignoring Environmental and Climatic Zone Compatibility

Packaging performance can vary drastically under different climatic conditions. Regulatory bodies like WHO and CDSCO expect data covering ICH Zones I–IVb if the product is intended for global markets.

• Use high-barrier containers (e.g., Type I glass, PVDC blister) for Zone IVb (hot and humid)
• Simulate shipping and storage in high-stress environments
• Ensure closures don’t lose torque or seal strength under thermal cycling

Failure to account for regional stress can lead to leakage, delamination, and microbial ingress.

7. Non-Validated Sealing Equipment or Inconsistent Process Control

Even with the right container and closure, improper sealing can compromise stability results. Regulatory inspections often uncover inconsistencies in crimping, torque application, or capping processes.

• Use calibrated and qualified sealing equipment
• Validate torque ranges or crimp depths
• Document process control checks in batch records

Consult equipment qualification references for process validation protocols.

8. Failing to Requalify Closures After Vendor Change

Many companies treat a vendor switch as a logistical change. However, regulators view it as a critical quality attribute. Even slight variations in stopper material, coating, or dimensions can affect integrity and leachables.

• Re-evaluate E&L profiles
• Revalidate CCI and sealing process
• Update closure specifications and change control logs
• Perform a bridging stability study if warranted

9. Overlooking Secondary Packaging’s Role in Stability

Some regulatory rejections have stemmed from inadequate secondary packaging. Cartons, trays, and overwraps affect light, moisture, and mechanical protection—especially in long-term storage.

• Ensure secondary packaging protects the container system during transport and storage
• Conduct drop tests, UV aging, and compression studies
• Include labeling adhesion tests under humidity and heat stress

10. Incomplete SOPs and Training for Closure Handling

GMP inspections often identify SOP gaps for closure receipt, inspection, sealing, and documentation. Regulatory concerns increase if operators lack adequate training or if SOPs lack clarity.

Ensure SOPs cover:

• Closure sampling and inspection
• In-process checks for sealing integrity
• Cleaning and storage of closures
• Deviation and corrective action tracking

See SOP training pharma for relevant templates.

Case Study: FDA 483 Issued for Incomplete Container Validation

A US-based manufacturer received a Form 483 observation during a pre-approval inspection because their commercial product was stored in HDPE bottles, while stability batches were placed in glass. No justification or bridging data was provided. The FDA required repeat stability studies and delayed product approval by 9 months. This case underscores the importance of alignment between development and commercial packaging.

Conclusion

Container and closure selection is a high-impact area of regulatory scrutiny in stability studies. From mismatched materials to inadequate documentation, every misstep can trigger data integrity concerns or compliance findings. A proactive, data-driven, and risk-based approach is essential. By avoiding these ten regulatory pitfalls, pharmaceutical companies can protect their product quality, accelerate approvals, and strengthen inspection readiness.

References:

• ICH Q1A(R2): Stability Testing of New Drug Substances and Products
• USP : Container Closure Integrity Testing
• WHO Technical Report Series on Pharmaceutical Packaging
• EMA Guideline on Plastic Immediate Packaging Materials
• FDA Guidance for Industry: Container Closure Systems